CRISPR opens the door on crop research by smaller companies and universities

CALS PlantScience
Image source: North Carolina State University

CRISPR, a new gene-editing technique, offers an end run around the cost associated with traditional genetic engineering, allowing smaller companies and public institutions to enter the market. Not only that, but crops with a market too small to be of interest to GM researchers are now in play.

Research is also being accelerated because the capital costs to participate areย dropping. In 2001, it cost $100 million to sequence a genome. By 2015, the cost had declined to $1,000. The continuing decline in the cost of computing and cloud data storage has allowed small companies to maintain data sets that a decade ago could have been supported only by the Monsantos of the world.

CRISPR research is being done to increase yields, nutrients, and resistance to disease and pests, improve photosynthesis and drought tolerance, and develop plants that can thrive in a changing climate. Not all of these projects will be successful, and weโ€™re a long way from a risk-based regulatory scheme that makes sense, but gene editing holds great promise.

It hardly seems necessary at this late date to point out the obvious, but I will anyway.ย Every regulatory agency in the world that has examined these breeding techniques has found them safe.

Read full, original post:ย CRISPR Will Make GMOs Ubiquitous

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosateโ€”the world's most heavily-used herbicideโ€”pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-04-22-at-12.21.32-PM
Viewpoint: Why the retracted Monsanto glyphosate study doesnโ€™t change the scienceโ€”the worldโ€™s most popular herbicide is safeย 
Picture1
The FDA couldnโ€™t find a vaccine safety crisis, so it buried its own research
ChatGPT-Image-May-1-2026-11_42_59-AM-2
Viewpoint: NAD is the wellness grifters latest evidence-lite longevity fad. At least the mice are impressed.
global warming
โ€˜Implausibleโ€™: Top climate scientists reject worst-case scenarioโ€”soaring temperatures and fast-rising sea levels
Screenshot-2026-05-21-at-12.15.17-PM
UK gene-editing milestone: Livestock barley that increases ruminant value and reduces methane emissions is first-approved CRISPR crop
vax-misinformation-main
Facts & Fallacies Podcast: Limit free speech to blunt social media misinfo?
ChatGPT-Image-Apr-16-2026-02_56_53-PM
Financial incentives, over diagnosis, and weak oversight: Autism claims are driving up Medicare costs
Screenshot-2026-05-21-at-3.15.53-PM
Chiropractors may no longer be modern-day snake oil salesmen, but the benefits of their therapy are limitedโ€“at best
ChatGPT-Image-May-12-2026-11_27_01-AM-2
AI likely to improve health care, research showsโ€”but not for blacks and ethnic minorities
Screenshot-2026-05-20-at-5.11.17-PM
Viewpoint: No, sugar doesnโ€™t โ€˜feedโ€™ cancer โ€” common cancer myths, debunked

Sorry. No data so far.

glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.